Ubiquinone vs. Ubiquinol Supplementation
ConditionIVF
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age37-43
SponsorTrio Fertility
About this trial
The objective of this study is to determine if ubiquinol will result in improved reproductive outcomes in older women at a reduced oral dose compared to current standard treatment with ubiquinone.
Eligibility criteria
Qualifiers
Women age >37 and <43 years undergoing their first in vitro fertilization (IVF) cycle
Day 3 follicle-stimulating hormone (FSH) <12 IU/L with serum estradiol <250 pmol/L and normal thyroid-stimulating hormone (TSH) and Prolactin
Partner with semen analysis suitable for IVF or ICSI
Anti-müllerian hormone (AMH) > 3 pmol/L
Disqualifiers
Has been diagnosed with or treated for any endocrine abnormality within 3 years prior Note: Participants with a history of clinical or subclinical hypothyroidism may be eligible if thyroid stimulating hormone levels at screening are within normal limits and the participant has been on a stable dose of thyroid replacement medication (or on no replacement therapy) for at least 8 weeks.
Has a prolactin level above the upper limit of normal for the central laboratory
Has FSH >12.0 IU/L
Has a history of a full or partial resection of an ovary, including a history of ovarian cystectomy, or of any ovarian tumors limiting access to the ovary during ovum pick-up, e.g., endometriomas or teratomas measuring >10 mm
Trial design
Treatments tested in this trial
- Ubiquinone 200 Mg Oral Capsule
- Ubiquinol 100 MG Oral Capsule
Treatment groups
90 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov